Genital Diseases, Female News - LARVOL Sigma

Genital Diseases, Female

Welcome, Profile Billing Logout

160 Mechanisms of Action

«1 2...74 75 76 77 787980 81 82 83 84...110 111 »

|||||||||| Enrollment closed: High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Recruiting --> Active, not recruiting

|||||||||| Enrollment closed: Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=300, Active, not recruiting, Sponsor: Auxogyn, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  rilotumumab (AMG 102) / Amgen
Trial initiation date:  Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) -  Feb 10, 2014
P2, N=50, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Initiation date: Dec 2009 --> Oct 2010

||||||||||  rilotumumab (AMG 102) / Amgen
Enrollment closed:  Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) -  Feb 10, 2014
P2, N=50, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
Initiation date: Dec 2009 --> Oct 2010 Recruiting --> Active, not recruiting

|||||||||| Clinical: Vaginal vs. Laparoscopic Hysterectomy (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=100, Recruiting, Sponsor: Medical University of Graz

|||||||||| New P2 trial: ROS: Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI) (clinicaltrials.gov) - Feb 6, 2014
P2, N=50, Completed, Sponsor: Cairo University

||||||||||  Menopur (menotropin) / Ferring
Enrollment open:  An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos (clinicaltrials.gov) -  Feb 6, 2014
P=N/A, N=700, Recruiting,  Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  desogestrel/ethinylestradiol / Generic mfg.
Trial completion:  FOLLPRIM: Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders (clinicaltrials.gov) -  Feb 6, 2014
P2, N=66, Completed,  Sponsor: Instituto de Investigacion Sanitaria La Fe
Not yet recruiting --> Recruiting Not yet recruiting --> Completed

||||||||||  Proellex (telapristone oral) / AbbVie
Trial withdrawal:  Open-Label Extension Study to ZPE-202 (clinicaltrials.gov) -  Feb 5, 2014
P2, N=0, Withdrawn,  Sponsor: Repros Therapeutics Inc.
Not yet recruiting --> Completed Not yet recruiting --> Withdrawn

||||||||||  Proellex (telapristone oral) / AbbVie
Enrollment change:  Open-Label Extension Study to ZPE-202 (clinicaltrials.gov) -  Feb 5, 2014
P2, N=0, Withdrawn,  Sponsor: Repros Therapeutics Inc.
Not yet recruiting --> Withdrawn N=90 --> 0

|||||||||| Trial completion: Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome. (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=9, Completed, Sponsor: Laval University
N=90 --> 0 Active, not recruiting --> Completed

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial termination, Metastases:  Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma (clinicaltrials.gov) -  Feb 4, 2014
P1/2, N=19, Terminated,  Sponsor: Gynecologic Oncology Associates
Active, not recruiting --> Completed Recruiting --> Terminated; toxicities

||||||||||  Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change:  Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) -  Feb 4, 2014
P2, N=350, Recruiting,  Sponsor: Prima BioMed Ltd
Recruiting --> Terminated; toxicities N=1000 --> 350

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Metastases:  Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma (clinicaltrials.gov) -  Feb 4, 2014
P1/2, N=19, Terminated,  Sponsor: Gynecologic Oncology Associates
N=1000 --> 350 N=43 --> 19

|||||||||| Enrollment open: Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF (clinicaltrials.gov) - Feb 4, 2014
P2/3, N=50, Recruiting, Sponsor: Aristotle University Of Thessaloniki
N=43 --> 19 Active, not recruiting --> Recruiting

||||||||||  triptorelin / Generic mfg.
New P4 trial:  GTMLPSGI: GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT (clinicaltrials.gov) -  Feb 2, 2014
P4, N=328, Recruiting,  Sponsor: Centre Hospitalier Universitaire Ibn Rochd

|||||||||| Enrollment open: Single-step Versus Sequential Media in Preimplantation Embryo Development and Pregnancy Rates (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=200, Recruiting, Sponsor: Eugonia
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  Paclical (micellar paclitaxel) / Vivesto, HLB Bio Group
Enrollment change:  Cremophor EL: Study of Paclitaxel in Patients With Ovarian Cancer (clinicaltrials.gov) -  Feb 2, 2014
P3, N=789, Completed,  Sponsor: Oasmia Pharmaceutical AB
Not yet recruiting --> Recruiting N=650 --> 789

||||||||||  Paclical (micellar paclitaxel) / Vivesto, HLB Bio Group
Trial completion:  Cremophor EL: Study of Paclitaxel in Patients With Ovarian Cancer (clinicaltrials.gov) -  Feb 2, 2014
P3, N=789, Completed,  Sponsor: Oasmia Pharmaceutical AB
N=650 --> 789 Recruiting --> Completed

||||||||||  Iclusig (ponatinib) / Takeda, Otsuka
Trial initiation date:  Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) -  Jan 30, 2014
P=N/A, N=15, Not yet recruiting,  Sponsor: Washington University School of Medicine
Recruiting --> Completed Initiation date: Sep 2013 --> Apr 2014

|||||||||| New P4 trial: Fertilizations With Immotile Sperm: Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation (clinicaltrials.gov) - Jan 29, 2014
P4, N=50, Not yet recruiting, Sponsor: Rambam Health Care Campus

|||||||||| Enrollment open: IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing (clinicaltrials.gov) - Jan 28, 2014
P=N/A, N=50, Recruiting, Sponsor: Rambam Health Care Campus
Initiation date: Sep 2013 --> Apr 2014 Not yet recruiting --> Recruiting

|||||||||| Enrollment open: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Jan 28, 2014
P=N/A, N=2100, Recruiting, Sponsor: Gen-Probe, Incorporated
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  metformin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
New P1 trial, Biopsy:  Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) -  Jan 28, 2014
P1, N=18, Not yet recruiting,  Sponsor: Fox Chase Cancer Center

||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
New P4 trial:  Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures (clinicaltrials.gov) -  Jan 27, 2014
P4, N=100, Not yet recruiting,  Sponsor: Rambam Health Care Campus

||||||||||  megestrol / Generic mfg.
Trial initiation date, Head-to-Head:  Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer (clinicaltrials.gov) -  Jan 26, 2014
P2, N=130, Not yet recruiting,  Sponsor: University of Southern California
Not yet recruiting --> Recruiting Initiation date: Oct 2013 --> Mar 2014

||||||||||  Elonva (corifollitropin alfa) / Organon
New P4 trial:  Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI (clinicaltrials.gov) -  Jan 26, 2014
P4, N=80, Completed,  Sponsor: Aristotle University Of Thessaloniki

||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
New P3 trial:  Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) -  Jan 26, 2014
P3, N=946, Ongoing,  Sponsor: Merck KGaA`Merk KGaA

||||||||||  Torisel (temsirolimus) / Pfizer
Trial completion, Surgery, Metastases:  Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery (clinicaltrials.gov) -  Jan 26, 2014
P2, N=32, Completed,  Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2013 --> Mar 2014 Active, not recruiting --> Completed

||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Enrollment open:  Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) -  Jan 23, 2014
P4, N=75, Recruiting,  Sponsor: Gynecologic Oncology Associates
Active, not recruiting --> Completed Active, not recruiting --> Recruiting

||||||||||  Mifeprex (mifepristone) / Danco Laboratories
New P1 trial, Metastases:  Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) -  Jan 23, 2014
P1, N=22, Recruiting,  Sponsor: University of Chicago

||||||||||  buparlisib (AN2025) / Adlai Nortye
Trial initiation date, Metastases:  BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers (clinicaltrials.gov) -  Jan 22, 2014
P2, N=54, Not yet recruiting,  Sponsor: University of Utah
Active, not recruiting --> Recruiting Initiation date: Dec 2013 --> May 2014

||||||||||  leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Surgery:  Medical Treatment of Endometriosis-Associated Pelvic Pain (clinicaltrials.gov) -  Jan 22, 2014
P3, N=194, Completed,  Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Initiation date: Dec 2013 --> May 2014 Recruiting --> Completed

||||||||||  Invanz (ertapenem) / Merck (MSD)
Trial termination:  Pharmacokinetics and Safety of Ertapenem in the Postpartum Period (clinicaltrials.gov) -  Jan 21, 2014
P1, N=3, Terminated,  Sponsor: Daniel Benjamin
Recruiting --> Completed Recruiting --> Terminated; study terminated due to low subject accrual

||||||||||  Invanz (ertapenem) / Merck (MSD)
Enrollment change:  Pharmacokinetics and Safety of Ertapenem in the Postpartum Period (clinicaltrials.gov) -  Jan 21, 2014
P1, N=3, Terminated,  Sponsor: Daniel Benjamin
Recruiting --> Terminated; study terminated due to low subject accrual N=24 --> 3

||||||||||  metformin / Generic mfg.
Biomarker, New P2 trial:  Endometrial Cancer Biomarker Changes Following Exposure to Metformin (clinicaltrials.gov) -  Jan 21, 2014
P2, N=80, Not yet recruiting,  Sponsor: Jewish General Hospital

||||||||||  OPB-111001 / Otsuka
New P1/2 trial, Metastases:  A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer (clinicaltrials.gov) -  Jan 21, 2014
P1/2, N=79, Recruiting,  Sponsor: Otsuka Novel Products GmbH

||||||||||  saracatinib (AZD0530) / AstraZeneca
Trial completion:  SaPPrOC: Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) -  Jan 21, 2014
P2/3, N=107, Completed,  Sponsor: University College, London
N=24 --> 3 Active, not recruiting --> Completed

|||||||||| Trial initiation date: SOVS-CTG: Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=3500, Not yet recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Apr 2014

|||||||||| Clinical: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Regionshospitalet Viborg, Skive

|||||||||| Enrollment open: Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness (clinicaltrials.gov) - Jan 20, 2014
P0, N=20, Recruiting, Sponsor: ViroPan, Inc.
Initiation date: Oct 2013 --> Apr 2014 Not yet recruiting --> Recruiting

|||||||||| Enrollment open, HEOR, Surgery: Lymphedema in Endometrial Cancer (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=100, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  OPB-111001 / Otsuka
Enrollment open, Metastases:  A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer (clinicaltrials.gov) -  Jan 19, 2014
P1/2, N=79, Recruiting,  Sponsor: Otsuka Novel Products GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Trial completion: Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome (clinicaltrials.gov) - Jan 19, 2014
P1, N=42, Completed, Sponsor: G
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| Enrollment open: The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=32, Recruiting, Sponsor: Amy E Rothberg
Recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Preclinical: Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Duke University

|||||||||| Trial completion, HEOR: Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=1264, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| New P4 trial: FIREFLY: Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis (clinicaltrials.gov) - Jan 15, 2014
P4, N=20, Recruiting, Sponsor: Florida Hospital

||||||||||  Hepacid (pegargiminase) / Polaris Pharma
Enrollment change, Metastases:  Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma (clinicaltrials.gov) -  Jan 15, 2014
P1, N=89, Recruiting,  Sponsor: Polaris Group
Active, not recruiting --> Completed N=61 --> 89

||||||||||  mesalamine extended-release capsules / Generic mfg.
Trial completion:  Mesalamine to Reduce T Cell Activation in HIV Infection (clinicaltrials.gov) -  Jan 15, 2014
P4, N=30, Completed,  Sponsor: University of California, San Francisco
N=61 --> 89 Enrolling by invitation --> Completed